Cargando…

P734: CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE

Detalles Bibliográficos
Autores principales:	Katamesh, Bahga, Nanaa, Ahmad, He, Rong, Viswanatha, David, Greipp, Patricia, Nguyen, Phuong, Jevremovic, Dragan, Arana Yi, Cecilia, M Foran, James, Benga, Kebede, Gangat, Naseema, Mangaonkar, Abhishek, Saliba, Antoine, Patnaik, Mrinal, Hogan, William, Litzow, Mark, Tefferi, Ayalew, Shah, Mithun, Alkhateeb, Hassan, Al-Kali, Aref
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428924/ http://dx.doi.org/10.1097/01.HS9.0000969840.65989.e7

Ejemplares similares

Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience
por: Katamesh, Bahga, et al.
Publicado: (2022)

P722: CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
por: Sai Mittapalli, Amrutha, et al.
Publicado: (2023)

P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
por: Oum, Muhamad, et al.
Publicado: (2023)

P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
por: Basmaci, Rami, et al.
Publicado: (2023)

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
por: Al-Kali, Aref, et al.
Publicado: (2023)

Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study
por: Xie, Zhuoer, et al.
Publicado: (2021)

Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience
por: Nanaa, Ahmad, et al.
Publicado: (2021)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
por: Tefferi, Ayalew, et al.
Publicado: (2022)

U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity
por: Badar, Talha, et al.
Publicado: (2023)

Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms
por: Badar, Talha, et al.
Publicado: (2023)

Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
por: Shah, Mithun Vinod, et al.
Publicado: (2022)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
por: Gangat, Naseema, et al.
Publicado: (2023)

Mayo Clinic experience with 1123 adults with acute myeloid leukemia
por: Begna, Kebede H., et al.
Publicado: (2021)

Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
por: Baranwal, Anmol, et al.
Publicado: (2022)

Erythrocytosis associated with EPAS1(HIF2A), EGLN1(PHD2), VHL, EPOR or BPGM mutations: the Mayo Clinic experience
por: Gangat, Naseema, et al.
Publicado: (2022)

Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival
por: Gangat, Naseema, et al.
Publicado: (2023)

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm
por: Gangat, Naseema, et al.
Publicado: (2022)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
por: Ilyas, Rimal, et al.
Publicado: (2023)

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
por: Ghorab, Ahmad, et al.
Publicado: (2022)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
por: Tefferi, Ayalew, et al.
Publicado: (2023)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
por: Johnson, Isla M., et al.
Publicado: (2022)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
por: Gangat, Naseema, et al.
Publicado: (2023)

Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined Significance
por: Jevremovic, Dragan, et al.
Publicado: (2022)

Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
por: Abdallah, Mostafa, et al.
Publicado: (2023)

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
por: Lasho, Terra L., et al.
Publicado: (2018)

P1346: THE IMPACT OF CYTOTOXIC THERAPY ON THE RISK OF PROGRESSION AND DEATH IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE.
por: Marissa, LI, et al.
Publicado: (2023)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases
por: Abdelmagid, Maymona G., et al.
Publicado: (2022)

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
por: Mangaonkar, Abhishek A., et al.
Publicado: (2018)

A population-based study of chronic neutrophilic leukemia in the United States
por: Ruan, Gordon J., et al.
Publicado: (2020)

SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
por: Gangat, Naseema, et al.
Publicado: (2020)

To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant
por: Baranwal, Anmol, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_offitq990c291g2n0uff09ng00